Characterization of Patients With Poor-Risk Metastatic Renal-Cell Carcinoma: Results From a Pooled Clinical Trials Database
作者: Lana HamiehRana R. McKayXun LinRonit SimantovToni K. Choueiri
作者单位: 1Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
2Pfizer Oncology, Pfizer Inc, New York, NY
刊名: Clinical Genitourinary Cancer, 2018, Vol.16 (1), pp.13-20.e3
来源数据库: Elsevier Journal
DOI: 10.1016/j.clgc.2017.07.021
关键词: IMDC risk groupsMSKCC risk groupsPrognosisRisk stratificationTargeted therapy
英文摘要: Abstract(#br)Background(#br)Poor-risk patients with metastatic renal-cell carcinoma remain poorly characterized in prospective clinical trials. Therefore, we sought to provide a comprehensive analysis of this patient population, defined by 3 widely used prognostic models, treated with targeted therapy.(#br)Patients and Methods(#br)We conducted a pooled retrospective analysis of 4736 metastatic renal-cell carcinoma patients treated on phase 2 and 3 clinical trials. Poor-risk patients were defined according to the Memorial Sloan Kettering Cancer Center (MSKCC), International Metastatic Renal Cell Carcinoma Database Consortium (IMDC), and Hudes risk models. Baseline characteristics, overall survival, progression-free survival, objective response rate, and adverse events were reported in...
全文获取路径: Elsevier  (合作)
影响因子:1.429 (2012)